were not different, the rebound at 15min was significantly greater after DA than after somatostatin (p<0.02). When TRH was injected at the termination of somatostatin infusion, the rebound increase was significantly enhanced and the rebound peak appeared 45 min earlier than after a single somatostatin administration.
Similarly, hp GRF (1-44)-NH2 enhanced the postinhibitory rebound rises in 4 patients studied. These results indicate that the mechanism participating in the postinhibitory rebound rise is different between normal controls and acromegalic patients, and the rebound rises induced by somatostatin and DA might occur through the different mechanisms. Also, it is evident that the rebound phenomenon in acromegaly is possibly modified by endogenous hypothalamic releasing factors.
It is widely accepted that plasma levels of human pituitary hormones are apt to show rebound increases followed by returns to the control levels after the administration of inhibitory agents (Hall et al., 1973; Besser et al., 1974a; Leblank et al., 1976; Judd et al., 1978; Leebaw et al., 1978; Kaptein et al., 1980) . This rebound phenomenon might occur as a result of maintaining homeostatic hormone secretion. As a postinhibitory rebound rise in GH secretion is also observed in acromegaly (Besser et al., 1974b; Hanew et al., 1980) , home-HANEW et al.
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Japon. December 1984 ostasis of GH secretion might exist even in such a pathologic state. However, the etiology of acromegaly is not clear (Cryer and Daughaday 1977) , and the role of endogenous GH-RH (GH-releasing hormone) and GIH (GH-inhibiting hormone: somatostatin) on GH regulation in these patients is not elucidated.
To evaluate the GH regulating mechanism in acromegalic patients, postinhibitory rebound rises in GH secretion induced by GIH were studied in these cases and normal subjects, and were compared with another inhibitory agent, dopamine. Furthermore, known hypothalamic GH releasing factors, i. e. TRH and hp GRF (1-44) (human pancreas GH-releasing factor 1-44 NH2) (Guillemin et al., 1982) , in acromegaly were employed whether or not the rebound phenomenon is modified by these agents. at the termination of GIH infusion (at 75 min) all except one showed a much greater increase in the rebound phenomenon. These results are summarized in Fig. 3 . In spite of the similar GH inhibition during the GIH infusions, the postinhibitory rebound was clearly enhanced by TRH compared to single GIH administration (p<0.02 at 90, 105min, p<0.05 at 120min). (Fig. 4) .
Discussion
In this study, we demonstrated that the postinhibitory rebound increases in plasma GH are different between acromegalic patients and normal subjects, and between the agents employed. Also, it was evident that the postinhibitory GH increases induced by GIH were modified by the additional stimulation of hypothalamic hormones.
Although the exact mechanisms have not been studied well, the rebounds could be (Brazeau et al., 1974; Sheppard et al., 1979; Bethge et al., 1981) . In rat, the episodic GH secretion, i. e. formation of peak and trough, is not modified by the administration of GIH antiserum or by the destruction of GIH neurons (Ferland et al., 1976; Urman and Critchlaw 1983; Willoughby et al., 1983) . These results indicate a minor role, if any, of GIH in the rebound or the episodic elevation of plasma GH. Therefore, the difference in the rebound increase between acromegalic patients and normal controls can be explained by the difference in the regulation of GH release by the hypothalamic GH-RH and by the somatotrophs having different secretory properties, or by the different disappearance rate of GIH action exogenously administered. Concerning this, a reverse relashionship was observed in patients with prolactin-secreting pituitary adenoma which shows more quicked and more marked rebound increases in their plasma prolactin than normal subjects after the cessation of DA infusion (unpublished data). This might indicate the differences in the hormone secretory properties and of hormone regulatory mechanism in GH-and prolactin-secreting adenomas. In this study, every acromegalic patients examined was TRH and hpGRF (1-44) responsive, and the rebound GH rise induced by GIH was significantly enhanced by these hypothalamic hormones. This finding seems to indicate that endogenous GH-releasing factors (including GH-RH and TRH) can participate in the phenomenon when their secretions are increased in vivo. The magnitude of GH responses to a single administration of TRH and hpGRF (1-44), however, varied from case to case, and were not comparable with the combitation test of GIH plus TRH or GIH plus hpGRF (data not shown). These results indicate the different sensitivities of somatotrophs to TRH and hpGRF in the basal and suppressed. state. The fact that the episodic GH secretion in rats disappears after the administration of GH-RF antiserum or the destruction of the GH-RH nucleus indicates a possible role of endogenous GH-RH on the postinhibitory rebound phenomenon (Wehrenberg et al., 1982; Eikelbloom and Tannenbaum 1983) . The determination of the GH-RH concentration in pituitary portal vessels would provide a valid conclusion.
Although we could not find a significant correlation between the GH decrease due to GIH and the postinhibitory increase (r= stored hormone pool (during the inhibition) might account for the phenomenon, because the postinhibitory GH rise is seen even in the absence of a hypothalamic contribution (i. e. in vitro system) (Stachura 1976; Goodyer et al., 1977; Adams et al., 1981; Lawton et al,, 1981; Cowan et al., 1983) . The overshoot seen in the in vitro system may mainly reflect the intracellular GH secretory property of somatotrophs.
Following the termination of DA infusion in acromegaly, DA caused a more rapid and marked rebound increase in GH than GIH, though DA caused a similar decrease in GH to that in GIH in terms of maximal suppression and inhibitory area. The half disappearance time of DA is not clear, but is expected to be very short as that of norepinephrine is reported to be within 3 min (Benedict et al., 1978; Fitzgerald et al., 1979) . Although the exact difference between the effect of DA and GIH in degradation rate is not clear, the disappearance of the DA action might be quicker than that of the GIH action at the somatotroph level. In addition, it must be taken into consideration that DA has dual actions on GH release in man: a releasing effect via the hypothalamus, as it is seen in normal subjects, and a direct inhibitory effect on the pituitary gland (Tallo and Malarkey 1981; Marcovitz et al., 1982) . Therefore, it is possible that dopamine stimulates the GH releasing factor from peptidergic GH-RF neurons at the level of the median eminence which lies outside of the blood brain barrier (Martin 1973; Leebaw et al., 1978; Bansal et al., 1981) . If this is true, the stimulated GH-RF may enhance the rebound phenomenon.
In conclusion, the hypothalamic regulation and the secretory properties of somatotrophs might be different between acromegalic and normal subjects. Additionally, the action of DA in acromegaly is different from that of GIH. Also, the rebound phenomenon in acromegaly is possibly modified by exogenous or endogenous hypothalamic releasing factors.
The intracellular GH secretory property and the hypothalamic GH-RF would be more important than GIH in the homeostatic GH secretion in acromegaly.
